Page 1

COAC Immune PRESS RELEASE AC Immune Reports Third Quarter 2021 Financial Results and Provides Corporate Update Announced the first positive cognitive results for a Tau - targeting monoclonal antibody in mild - to- moderate Alzheimer's disease Closed its strategic acquisition of an industry - leading Parkinson's disease vaccine and an equity financing led by key investors Appointed Monica Shaw , M.D. , and Prof. Monika Bütler , Dr. Oec . , to the Board of Directors Strong financial position of CHF 188.6 million ensures the Company is fully financed through at least Q1 2024 Lausanne , Switzerland , November 8 , 2021 - AC Immune SA ( NASDAQ : ACIU ) , a clinical - stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases , today reported its financial results for the quarter ended September 30 , 2021 and provided a corporate update . Prof. Andrea Pfeifer , CEO of AC Immune SA , commented : “ AC Immune concluded an exceptional third quarter , highlighted by the acquisition of a clinical a - syn vaccine candidate in Parkinson's disease and topline Phase 2 Lauriet data showing that semorinemab was the first Tau antibody candidate to significantly slow cognitive decline in mild - to - moderate Alzheimer's disease patients . Our partner Genentech , a member of the Roche Group , will present the topline Lauriet data , later this week at the CTAD 2021 conference , where we will present new clinical data on our p - Tau and Abeta vaccine candidates , ACI - 35 and ACI - 24 , respectively . These achievements show the commitment , progress and breadth of our leadership in discovering and developing impactful therapeutics for neurodegenerative diseases . " Q3 2021 and Subsequent Highlights Announced the first positive cognitive results for a Tau - targeting monoclonal antibody in Alzheimer's disease ( AD ) . Topline data from the Lauriet Phase 2 trial of semorinemab in mild - to - moderate AD showed a statistically significant ( p < 0.0025 ) 43.6 % reduction at week 49 in cognitive decline vs. placebo as measured by ADAS - Cog11 , one of the trial's co- primary endpoints . The second co - primary endpoint , ADCS - ADL , was not met . AC Immune's partner Genentech is continuing with the trial's open label extension and is 1 Total cash position does not include total gross proceeds of USD 30 million received in October 2021 from ( i ) USD 5 million as part of the Affiris asset acquisition and ( ii ) USD 25 million as part of a private placement with select group of Affiris investors . 1/8